NGS-based liquid biopsies can identify actionable genetic alterations, guiding the selection of targeted therapies. For example, detecting specific mutations in EGFR or ALK genes in ctDNA from lung cancer patients can direct the use of appropriate tyrosine kinase inhibitors. Here, ALK is linked to lung carcinoma.